Company Overview
Company Type: Public Company
Website: www.titanmedicalinc.com
Number of Employees: 33
Ticker: TMD (TSX)
Year Founded: -


Business Description
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body during surgical procedures. The company is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
22.7
Market Capitalization
15.8
TEV/Total Revenue
0.2x
EBITDA
(11.8)
Total Enterprise Value
3.9
TEV/EBITDA
NM
EBIT
(12.3)
Cash & ST Invst.
14.4
P/Diluted EPS Before Extra
NM
Net Income
(16.7)
Total Debt
2.2
Price/Tang BV
1.9x
Capital Expenditure
(0.5)
Total Assets
17.5
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Cataford, Paul G.
Chairman, Interim President & CEO
Huang, Chien 
Chief Financial Officer

Key Board Members
Name
Title
Cataford, Paul G.
Chairman, Interim President & CEO
Giovinazzo, Anthony J.
Lead Independent Director
Steiner, Cathy Robin
Independent Director
Vance, Cary G.
Independent Director
Estape, Ricardo 
Member of Surgeon Advisory Board
Magnuson, J. Scott
Member of Surgeon Advisory Board
O’Brien, Daniel 
Independent Director
Song, Arleen H
Member of Surgeon Advisory Board
Stepp, Kevin J.E.
Member of Surgeon Advisory Board


Primary Industry Classification
Health Care Equipment


Primary Office Location
76 Berkeley Street | Toronto, ON | M5A 2W7 | Canada

Current and Pending Investors
Armistice Capital LLC, Intracoastal Capital LLC, Longtai Medical Inc., Shanghai Jugu Equity Investment Fund Co., Ltd.

Prior Investors
Mackenzie Financial Corporation

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.14
Market Cap (mm)
15.9
Open
 0.15
Shares Out. (mm)
113.5
Previous Close
 0.14
Float %
99.5%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.15/ 0.14
Diluted EPS Excl. Extra Items
(0.16)
52 wk High/Low
 1.60/ 0.14
P/Diluted EPS Before Extra
NM
Volume (mm)
0.02
Avg 3M Dly Vlm (mm)
0.06
Beta 5Y
3.56


 
Delayed Quote** | Last Updated on Oct-10-2023 12:00 AM (GMT-5)
TSX:TMD - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
KAM Capital Corp.
As of July 28, 2008, KAM Capital Corp. was acquired by Synergist Medical Inc., in a reverse merger transaction. KAM Capital Corp. is a capital pool company. The company was incorporated in 2007 and is based in Toronto, Canada.

United States and Canada
Asset Management and Custody Banks
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-15-2022
Apr-3-2023
Shelf Registration
Target
Titan Medical Inc. (TSX:TMD)


12.51
Aug-19-2022
-
Shelf Registration
Target
Titan Medical Inc. (TSX:TMD)


90.00
Apr-23-2021
Apr-3-2023
Shelf Registration
Target
Titan Medical Inc. (TSX:TMD)


7.41
Feb-2-2021
Feb-24-2021
Public Offering
Target
Titan Medical Inc. (TSX:TMD)


20.00
Jan-5-2021
Jan-26-2021
Public Offering
Target
Titan Medical Inc. (TSX:TMD)


10.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-21-2023
Client Announcements
Titan Medical Signs License Agreement with Auris Health, Inc
Aug-14-2023
Executive/Board Changes - Other
Titan Medical Inc. Appoints Daniel O’Brien as A New Independent Member to Its Board of Directors
Jun-30-2023
Annual General Meeting
Titan Medical Inc., Annual General Meeting, Jun 30, 2023
Jun-30-2023
Shareholder/Analyst Calls
Titan Medical Inc. - Shareholder/Analyst Call
Jun-20-2023
Business Reorganizations
Titan Medical Successfully Transitions to an IP Licensing Company

Competitors
AB SKF (publ) (OM:SKF B), Akebono Brake Corporation, APC Automotive Technologies LLC, Applied Medical Resources Corporation, Auris Health, Inc., Autolite (India) Limited (BSE:500029), Avateramedical GmbH, Brake Parts Inc. LLC., CMR Surgical Limited, Crowne Group, LLC, Dana Incorporated (NYSE:DAN), DENSO Corporation (TSE:6902), Distalmotion SA, Dorman Products, Inc. (NasdaqGS:DORM), DPH Holdings Corp., Gri Engineering & Development, Llc, Intuitive Surgical, Inc. (NasdaqGS:ISRG), ITW Global Brands, Inc., Johnson & Johnson (NYSE:JNJ), MAHLE GmbH, Medicaroid Corporation, Medicaroid Inc, Medrobotics Corporation, Medtronic plc (NYSE:MDT), meerecompany Incorporated (KOSDAQ:A049950), Mevotech LP, MicroPort Scientific Corporation (SEHK:853), Neapco Inc., Niterra Co., Ltd. (TSE:5334), NTN Bearing Corporation Of America, Old World Industries, LLC, Olympus Corporation (TSE:7733), Osram Sylvania Ltd., Phillips Industries, Inc., Pylon Manufacturing Corporation, Robert Bosch GmbH, Samsung C&T Corporation (KOSE:A028260), Samsung Electronics Co., Ltd. (KOSE:A005930), Shandong Weigao Group Medical Polymer Company Limited (SEHK:1066), Shanghai MicroPort MedBot (Group) Co., Ltd. (SEHK:2252), The Timken Company (NYSE:TKR), Trico Products Corporation, Valeo SE (ENXTPA:FR), Verb Surgical Inc., Vicarious Surgical Inc. (NYSE:RBOT), Weigao Holding Company Limited, ZF TRW Automotive Holdings Corp.

M&A Advisors
Borden Ladner Gervais LLP


Advisors
Most Recent Auditor
BDO LLP
M&A Advisors
Borden Ladner Gervais LLP
Private Placement Advisors
Dorsey & Whitney LLP, Union Securities Ltd.
Public Offering Advisors
BDO Canada LLP, BDO LLP, Borden Ladner Gervais LLP, Dorsey & Whitney LLP, H.C. Wainwright & Co., LLC, Moore Stephens Cooper Molyneux LLP, Northland Securities, Inc.
Key development Advisor
Raymond James Financial, Inc. (NYSE:RJF)


Most Recent Auditor
BDO LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:47 AM
TMD
Titan Medical Inc 2023_10_05
Reports
14
GlobalData

Oct 03, 2023 12:38 AM
TMD
Titan Medical Inc (TMD.TSE) - Financial and Strategic SWOT Analysis Review
Reports
175
S&P Global Compustat

Sep 07, 2023 03:34 AM
TMD
Titan Medical Inc 2023_09_07
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Sep 06, 2023 06:00 PM
TMD
Rating Update for Titan Medical Inc
EPS Estimates*
3
GlobalData

Sep 04, 2023 08:06 PM
TMD
Titan Medical Inc (TMD.TSE) - Financial and Strategic SWOT Analysis Review
Reports
176
ValuEngine, Inc.

Sep 01, 2023 03:43 AM
TMD
ValuEngine - Toronto Quantitative Stock Report for TMD
Reports
9
GlobalData

Aug 18, 2023 03:39 AM
TMD
Titan Medical Inc (TMDI.NASD) - Medical Equipment - Deals and Alliances Profile
Reports
69
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 02, 2023 06:00 PM
TMD
Rating Update for Titan Medical Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 17, 2023 06:41 AM
TMD
Rating Update for Titan Medical Inc
EPS Estimates*
3
S&P Global Compustat

Jul 06, 2023 03:16 AM
TMD
Titan Medical Inc 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


O’Brien M.B.A., M.D., Ph.D., Daniel 

312,389

0.28

0.0

Aug-11-2023


Bg Fund Management Luxembourg S.A.

164,350

0.14

0.0

Jun-30-2023


Cataford B.Sc., M.B.A., Paul G.

136,762

0.12

0.0

May-16-2023


Galfetti, Kristen P.

36,454

0.03

0.0

Dec-16-2022


First Heartland Consultants, Inc.

33,657

0.03

0.0

Jun-30-2023


Seibert, Christopher 

27,006

0.02

0.0

Dec-16-2022


Carrea, Tammy Barnes

25,659

0.02

0.0

Dec-28-2022


MAI Capital Management, LLC

20,031

0.02

0.0

Jun-30-2023


Vance, Cary G.

15,000

0.01

0.0

May-16-2023


B.E.S.T. Investment Counsel Limited

14,716

0.01

0.0

Feb-28-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
O’Brien M.B.A., M.D., Ph.D., Daniel 
312,389
312,389

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Essex LLC
0
(2,857,640)
Waterford Advisors, LLC
0
(101,046)
Barker, John E.
0
(45,714)
Vance, Cary G.
15,000
(43,577)
Avion Wealth, LLC
0
(40,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Enos Robotic Single Access Surgical System (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-21-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
News Releases
127 KB
Aug-10-2023
Jun-30-2023
Titan Medical Inc. (TSX:TMD)
SEDAR
Interim Financial Statements
397 KB
Aug-10-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
News Releases
138 KB
Jul-04-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
Management Proxy Materials
175 KB
Jul-04-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
News Releases
149 KB
Jun-20-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
News Releases
160 KB
Jun-16-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
News Releases
169 KB
Jun-14-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
Material Change Report
284 KB
Jun-14-2023
-
Titan Medical Inc. (TSX:TMD)
SEDAR
Documents Affecting the Rights of Security Holders
114 KB
Jun-09-2023
Mar-31-2023
Titan Medical Inc. (TSX:TMD)
SEDAR
Interim Financial Statements
395 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Carrea, Tammy Barnes
Dec-28-2022
Common Shares
13,259
0
Derivative Exercise and Retained Stock
106.93
Multiple
Carrea, Tammy Barnes
Dec-28-2022
Common Shares
(6,741)
(6,586)
Derivative Exercise and Sale
-
Multiple
-
Dec-28-2022
Common Shares
6,741
0
Derivative Exercise
-
Exchange Announcement
-
Dec-28-2022
Common Shares
(6,741)
(6,586)
Sale
-
Exchange Announcement
Vance, Cary G. (Independent Director)
Dec-28-2022
Common Shares
43,577
0
Derivative Exercise and Retained Stock
290.51
Multiple
Carrea, Tammy Barnes
Aug-31-2022
Common Shares
20,707
14,752
Derivative Exercise and Retained Stock
(249.27)
Multiple
Carrea, Tammy Barnes
Aug-31-2022
Common Shares
(8,307)
(5,918)
Open Market Disposition
(40.12)
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Cataford, Paul G.
Chairman, Interim President & CEO
(416) 359-8076
-

Giovinazzo, Anthony J.
Lead Independent Director
-
-

Steiner, Cathy Robin
Independent Director
-
-

Vance, Cary G.
Independent Director
-
-

Estape, Ricardo 
Member of Surgeon Advisory Board
-
-

Magnuson, J. Scott
Member of Surgeon Advisory Board
-
-

O’Brien, Daniel 
Independent Director
-
-

Song, Arleen H
Member of Surgeon Advisory Board
-
-

Stepp, Kevin J.E.
Member of Surgeon Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cataford, Paul G.
Chairman, Interim President & CEO
(416) 359-8076
-

Huang, Chien 
Chief Financial Officer
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
